Literature DB >> 29053140

Measurement of BH3-only protein tolerance.

Haiming Dai1,2,3,4, Husheng Ding3,4, Kevin L Peterson3, X Wei Meng3,4, Paula A Schneider3, Katherine L B Knorr4, Scott H Kaufmann3,4.   

Abstract

The BCL2 family of proteins regulates cellular life and death decisions. Among BCL2 family members, BH3-only proteins have critical roles by neutralizing antiapoptotic family members, as well as directly activating BAX and BAK. Despite widespread occurrence of BH3-only protein upregulation in response to various stresses, this process is rarely quantified. Moreover, it is unclear whether all BH3-only proteins are equipotent at inducing cell death. Here we show that BH3-only proteins increase as much as 15- to 20-fold after various treatments and define a parameter, termed BH3-only tolerance, which measures how many copies of a particular BH3-only protein can be expressed before the majority of cells in a population undergo apoptosis. We not only assess the relative contributions of anti- and proapoptotic BCL2 family members to BH3-only tolerance, but also illustrate how the study of this parameter can be used to understand cellular sensitivity to anticancer drugs and new combinations. These observations provide a new quantitative framework for assessing apoptotic susceptibility under various conditions.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29053140      PMCID: PMC5762843          DOI: 10.1038/cdd.2017.156

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  60 in total

Review 1.  The Bcl-2 family: roles in cell survival and oncogenesis.

Authors:  Suzanne Cory; David C S Huang; Jerry M Adams
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

2.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

3.  BH3-triggered structural reorganization drives the activation of proapoptotic BAX.

Authors:  Evripidis Gavathiotis; Denis E Reyna; Marguerite L Davis; Gregory H Bird; Loren D Walensky
Journal:  Mol Cell       Date:  2010-11-12       Impact factor: 17.970

4.  MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.

Authors:  K L B Knorr; P A Schneider; X W Meng; H Dai; B D Smith; A D Hess; J E Karp; S H Kaufmann
Journal:  Cell Death Differ       Date:  2015-06-05       Impact factor: 15.828

5.  Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity.

Authors:  Rogier W Rooswinkel; Bert van de Kooij; Evert de Vries; Madelon Paauwe; Rens Braster; Marcel Verheij; Jannie Borst
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

6.  Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins.

Authors:  Nathan W Werneburg; M Eugenia Guicciardi; Steve F Bronk; Scott H Kaufmann; Gregory J Gores
Journal:  J Biol Chem       Date:  2007-08-08       Impact factor: 5.157

Review 7.  Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies.

Authors:  Alex R D Delbridge; Stephanie Grabow; Andreas Strasser; David L Vaux
Journal:  Nat Rev Cancer       Date:  2016-02       Impact factor: 60.716

8.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.

Authors:  S J Martin; C P Reutelingsperger; A J McGahon; J A Rader; R C van Schie; D M LaFace; D R Green
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

9.  The elimination of miR-23a in heat-stressed cells promotes NOXA-induced cell death and is prevented by HSP70.

Authors:  R Roufayel; D S Johnston; D D Mosser
Journal:  Cell Death Dis       Date:  2014-11-27       Impact factor: 8.469

10.  Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax.

Authors:  C Hockings; K Anwari; R L Ninnis; J Brouwer; M O'Hely; M Evangelista; M G Hinds; P E Czabotar; E F Lee; W D Fairlie; G Dewson; R M Kluck
Journal:  Cell Death Dis       Date:  2015-04-23       Impact factor: 8.469

View more
  8 in total

Review 1.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

Review 2.  BAX, BAK, and BOK: A Coming of Age for the BCL-2 Family Effector Proteins.

Authors:  Tudor Moldoveanu; Peter E Czabotar
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

3.  KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells.

Authors:  Zhi-Chuan Zhu; Ji-Wei Liu; Kui Li; Jing Zheng; Zhi-Qi Xiong
Journal:  Oncogene       Date:  2018-03-09       Impact factor: 9.867

4.  MiR-35 buffers apoptosis thresholds in the C. elegans germline by antagonizing both MAPK and core apoptosis pathways.

Authors:  Anh T Tran; Eric M Chapman; Mathieu N Flamand; Bin Yu; Samuel J Krempel; Thomas F Duchaine; Matthew Eroglu; W Brent Derry
Journal:  Cell Death Differ       Date:  2019-04-05       Impact factor: 15.828

Review 5.  BH3-Only Proteins Noxa and Puma Are Key Regulators of Induced Apoptosis.

Authors:  Rabih Roufayel; Khaled Younes; Ahmed Al-Sabi; Nimer Murshid
Journal:  Life (Basel)       Date:  2022-02-09

6.  A Probabilistic Approach to Explore Signal Execution Mechanisms With Limited Experimental Data.

Authors:  Michael A Kochen; Carlos F Lopez
Journal:  Front Genet       Date:  2020-07-10       Impact factor: 4.599

7.  Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Authors:  Warren Fiskus; Tianyu Cai; Courtney D DiNardo; Steven M Kornblau; Gautam Borthakur; Tapan M Kadia; Naveen Pemmaraju; Prithviraj Bose; Lucia Masarova; Kimal Rajapakshe; Dimuthu Perera; Cristian Coarfa; Christopher P Mill; Dyana T Saenz; David N Saenz; Baohua Sun; Joseph D Khoury; Yu Shen; Marina Konopleva; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2019-01-15       Impact factor: 11.037

8.  Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.

Authors:  Dongyan Liu; Xiaonan Hou; Wangyu Wu; Valentina Zanfagnin; Yunjian Li; Cristina Correia; Zhiyang Zhao; Chenggang Zhao; Zhirong Liu; Tao Zhang; Zhiyou Fang; Hongzhi Wang; Chao Xu; Saravut J Weroha; Scott H Kaufmann; Haiming Dai
Journal:  Cell Death Dis       Date:  2021-08-12       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.